Kirchengast M[au] - Search Results

Year	Number of Results
1987	1
1988	1
1989	2
1990	1
1991	1
1993	1
1994	1
1995	5
1996	2
1997	1
1998	12
1999	8
2000	7
2001	5
2002	3
2003	2
2004	1
2005	2
2006	1
2007	1
2019	2
2020	1
2022	0

1

Endothelin and restenosis.

Kirchengast M, Münter K. Kirchengast M, et al. Cardiovasc Res. 1998 Sep;39(3):550-5. doi: 10.1016/s0008-6363(98)00143-6. Cardiovasc Res. 1998. PMID: 9861296 Review. No abstract available.

2

Endothelin receptor antagonists: clinical realities and future directions.

Kirchengast M, Luz M. Kirchengast M, et al. J Cardiovasc Pharmacol. 2005 Feb;45(2):182-91. doi: 10.1097/01.fjc.0000152030.61620.57. J Cardiovasc Pharmacol. 2005. PMID: 15654268 Review.

3

Towards a novel continuous HME-Tableting line: Process development and control concept.

Sacher S, Celikovic S, Rehrl J, Poms J, Kirchengast M, Kruisz J, Sipek M, Salar-Behzadi S, Berger H, Stark G, Horn M, Khinast JG. Sacher S, et al. Among authors: kirchengast m. Eur J Pharm Sci. 2020 Jan 15;142:105097. doi: 10.1016/j.ejps.2019.105097. Epub 2019 Oct 21. Eur J Pharm Sci. 2020. PMID: 31648048

4

Ensuring tablet quality via model-based control of a continuous direct compaction process.

Kirchengast M, Celikovic S, Rehrl J, Sacher S, Kruisz J, Khinast J, Horn M. Kirchengast M, et al. Int J Pharm. 2019 Aug 15;567:118457. doi: 10.1016/j.ijpharm.2019.118457. Epub 2019 Jun 28. Int J Pharm. 2019. PMID: 31255779

5

Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling.

Kirchengast M, Münter K. Kirchengast M, et al. Proc Soc Exp Biol Med. 1999 Sep;221(4):312-25. doi: 10.1046/j.1525-1373.1999.d01-88.x. Proc Soc Exp Biol Med. 1999. PMID: 10460693 Review.

6

Targets for endothelin in the diseased kidney: clues for therapeutic intervention.

Rohmeiss P, Birck R, Braun C, Kirchengast M, van der Woude FJ. Rohmeiss P, et al. Among authors: kirchengast m. Exp Nephrol. 1999 Jan-Feb;7(1):1-10. doi: 10.1159/000020577. Exp Nephrol. 1999. PMID: 9892807 Review.

7

Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.

Wölkart G, Pang X, Stessel H, Kirchengast M, Brunner F. Wölkart G, et al. Among authors: kirchengast m. Br J Pharmacol. 2007 Aug;151(8):1187-97. doi: 10.1038/sj.bjp.0707325. Epub 2007 Jun 18. Br J Pharmacol. 2007. PMID: 17572700 Free PMC article.

8

Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.

Kirchengast M. Kirchengast M. J Hypertens Suppl. 1997 Mar;15(2):S27-33. J Hypertens Suppl. 1997. PMID: 9218195 Review.

9

Nonviral monocyte chemoattractant protein-1 gene transfer improves arteriogenesis after femoral artery occlusion.

Muhs A, Lenter MC, Seidler RW, Zweigerdt R, Kirchengast M, Weser R, Ruediger M, Guth B. Muhs A, et al. Among authors: kirchengast m. Gene Ther. 2004 Dec;11(23):1685-93. doi: 10.1038/sj.gt.3302360. Gene Ther. 2004. PMID: 15470479

10

Effects of chronic endothelin ET(A) receptor blockade on blood pressure and vascular formation of cyclic guanosine-3',5'-monophosphate in spontaneously hypertensive rats.

Kirchengast M, Witte K, Stolpe K, Schilling L, Nedvetsky PI, Schmidt HH, Lemmer B. Kirchengast M, et al. Arzneimittelforschung. 2005;55(9):498-504. doi: 10.1055/s-0031-1296896. Arzneimittelforschung. 2005. PMID: 16229113

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results